Skip to main content
. 2020 Nov 11;34(1):e00115-20. doi: 10.1128/CMR.00115-20

TABLE 16.

Different resistance mechanisms among Enterobacterales and P. aeruginosa against four approved new BLBLIsa

Drugb Resistance mechanisms
CAZ-AVI Class B MBLs
Hyperexpression of efflux pumps
Porin alterations
Increased expression of the blaKPC gene or mutations on Ω-loop of KPC enzymes
Mutations in PBPs (rare)
TOL-TAZ Class A β-lactamases (some of ESBLs, mainly K. pneumoniae, most of KPCs)
Class B MBLs
Hyperproduction of AmpC (not in P. aeruginosa)
Class D carbapenemases (OXA-48-like)
MER-VAB Class B MBLs
Class D carbapenemases (OXA-48-like)
Porin alterations
Hyperexpression of efflux pumps
IMI-REL Class B MBLs
Class D carbapenemases (OXA-48-like)
Specific class A carbapenemases (e.g., GES)
Hyperexpression of KPC
Porin alterations
a

See references 325, to ,329.

b

CAZ-AVI, ceftazidime-avibactam; TOL-TAZ, ceftolozane-tazobactam; MER-VAB, meropenem-vaborbactam; IMI-REL, imipenem-relebactam.